Oncology

Ramucirumab approved as a single-agent treatment and in combination with chemotherapy.

Treatment developed by Amgen fails to demonstrate statistically significant improvement in overall survival.

Dispensing generic hormonal therapies instead of their brand-name counterparts increases breast cancer patients' life-saving medication adherence by 50%.

The CHEST Foundation recently launched its Lung Cancer Care: A Team Approach campaign as part of National Lung Cancer Awareness Month. The campaign aims to raise awareness about low treatment rates and the importance of medical specialists working together to provide optimal lung cancer care.

Patients with early stage tumors fare worse with erlotinib than if they take nothing.

Bortezomib found to effectively treat chronic graft-versus-host disease.

Accelerated approval for pembrolizumab based on tumor response rate and durability of response.

The FDA today granted breakthrough therapy designation to a new treatment for non-small cell lung cancer patients.

Nanotechnology and shortwave infrared light reveals small tumors and cardiovascular lesions deep inside body.

Cyramza (ramucirumab) was approved for treatment of patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma after disease progression.

Adults aged 50 years or older who feel comfortable about aging are more likely to seek preventive health care services.

In the pediatric hospital setting, pharmacists most frequently perform drug therapy changes on the cancer ward.

Treatment inhibits key process that enables cancer cells to multiply.

An estimated 6.9 million US adults aged 35 years and older had a combined 10.9 million self-reported smoking-attributable medical conditions in 2009.

The vaccine that prevents illness and death from pneumococcal infection also combats severe antibiotic-resistant disease in young children.

Palbociclib provides first-line systemic treatment for women with advanced or metastatic breast cancer.

The FDA today granted priority review status to a breakthrough breast cancer drug developed by Pfizer Inc.

In a retrospective study, investigators found that increases in total cholesterol and triglycerides were associated with an increased risk of biochemical recurrence in prostate cancer.

The drug combination prevents nausea and vomiting after the start of cancer chemotherapy.

The drug combination prevents nausea and vomiting after the start of cancer chemotherapy.

Brand name, patent-protected medications drive increasing costs.

Researcher urges caution in prescribing testosterone therapy in men who have not been diagnosed with hypogonadism.

Tobacco users have an increased risk of oral human papillomavirus type 16, a sexually transmitted virus that is strongly associated with cervical cancer.

Researchers in Finland are learning more about how hormones influence the risk of developing breast cancer, which may lead to a hormone-based treatment to reduce the risk of developing cancer later in life.